Literature DB >> 10208156

Synaptic synthesis of the Fragile X protein: possible involvement in synapse maturation and elimination.

I J Weiler1, W T Greenough.   

Abstract

Fragile X mental retardation syndrome results from the absence of or a defect in the protein (FMRP) encoded by the FMR1 gene. FMRP is found in dendrites and synapses as well as in the neuronal cell soma and nucleus, and although it is known to bind to RNA, the function of the protein in neurons is not known. We have studied activity-dependent changes in postsynaptically localized protein translation in central nervous system neurons. We find that FMRP is one of the proteins produced at synapses following stimulation of metabotropic glutamate receptors. We have also observed that Fragile X knockout mice, like human Fragile X patients, have excess numbers of long, thin, immature-appearing dendritic processes. Together, these findings suggest that FMRP plays a role in the process whereby synaptic activity during development results in structural and functional maturation of the synapse. We hypothesize that synaptic synthesis of FMRP may be essential for activity-based synapse maturation and elimination, a key process in normal brain development.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10208156     DOI: 10.1002/(sici)1096-8628(19990402)83:4<248::aid-ajmg3>3.0.co;2-1

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  49 in total

1.  Are there specific disabilities of number processing in adolescent patients with Anorexia nervosa? Evidence from clinical and neuropsychological data when compared to morphometric measures from magnetic resonance imaging.

Authors:  K J Neumärker; W M Bzufka; U Dudeck; J Hein; U Neumärker
Journal:  Eur Child Adolesc Psychiatry       Date:  2000       Impact factor: 4.785

Review 2.  Protein synthesis in the dendrite.

Authors:  Shao Jun Tang; Erin M Schuman
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2002-04-29       Impact factor: 6.237

3.  Characterization and reversal of synaptic defects in the amygdala in a mouse model of fragile X syndrome.

Authors:  Aparna Suvrathan; Charles A Hoeffer; Helen Wong; Eric Klann; Sumantra Chattarji
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-07       Impact factor: 11.205

4.  Subcellular localization of fragile X mental retardation protein with the I304N mutation in the RNA-binding domain in cultured hippocampal neurons.

Authors:  M Castrén; A Haapasalo; B A Oostra; E Castrén
Journal:  Cell Mol Neurobiol       Date:  2001-02       Impact factor: 5.046

5.  A comparison of pragmatic language in boys with autism and fragile X syndrome.

Authors:  Jessica Klusek; Gary E Martin; Molly Losh
Journal:  J Speech Lang Hear Res       Date:  2014-10       Impact factor: 2.297

6.  Exploring the zebra finch Taeniopygia guttata as a novel animal model for the speech-language deficit of fragile X syndrome.

Authors:  Claudia Winograd; Stephanie Ceman
Journal:  Results Probl Cell Differ       Date:  2012

7.  Gender-specific effect of Mthfr genotype and neonatal vigabatrin interaction on synaptic proteins in mouse cortex.

Authors:  Elinor Blumkin; Tamar Levav-Rabkin; Osnat Melamed; Dalia Galron; Hava M Golan
Journal:  Neuropsychopharmacology       Date:  2011-04-13       Impact factor: 7.853

Review 8.  The state of synapses in fragile X syndrome.

Authors:  Brad E Pfeiffer; Kimberly M Huber
Journal:  Neuroscientist       Date:  2009-03-26       Impact factor: 7.519

9.  Fragile X mental retardation protein regulates synaptic and behavioral plasticity to repeated cocaine administration.

Authors:  Laura N Smith; Jakub P Jedynak; Miles R Fontenot; Carly F Hale; Karen C Dietz; Makoto Taniguchi; Feba S Thomas; Benjamin C Zirlin; Shari G Birnbaum; Kimberly M Huber; Mark J Thomas; Christopher W Cowan
Journal:  Neuron       Date:  2014-05-07       Impact factor: 17.173

Review 10.  Gene, brain, and behavior relationships in fragile X syndrome: evidence from neuroimaging studies.

Authors:  Amy A Lightbody; Allan L Reiss
Journal:  Dev Disabil Res Rev       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.